Association of aortic vascular uptake of
18FDG PET/CT
Atherosclerosis
Inflammation
Psoriasis
Thoracic MRI
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
20
05
2019
accepted:
18
07
2019
pubmed:
7
8
2019
medline:
12
9
2020
entrez:
7
8
2019
Statut:
ppublish
Résumé
The contribution of inflammation to the incidence of cardiovascular disease (CVD) has been increasingly recognized in recent years. We investigated the relationship of aortic vascular uptake of 18F-FDG by PET/CT and aortic wall thickness (AWT) by MRI in psoriasis, a chronic inflammatory disease with increased incidence of CVD. One hundred sixty-five patients with plaque psoriasis participated in an ongoing longitudinal cohort study. Subclinical atherosclerosis was assessed as aortic uptake of 18F-FDG by PET/CT reported as target-to-background ratio (TBR) and AWT by MRI reported as maximal thickness. Patients with psoriasis were middle aged, predominantly male, and had mild CV risk by traditional risk factors. Psoriasis severity as measured by PASI score was a notable determinant of AWT (ρ = 0.20, p = 0.01). Moreover, aortic vascular uptake of 18F-FDG associated with AWT by MRI at baseline in unadjusted analysis (β = 0.27 p = 0.001) and following adjustment for traditional cardiovascular risk factors, waist-to-hip ratio, and statin use (β = 0.21 p = 0.01). Finally, following 1 year of psoriasis treatment, a decrease in aortic vascular uptake of 18F-FDG was associated with a reduction in AWT in fully adjusted models (β = 0.33, p = 0.02). In conclusion, we demonstrate that psoriasis severity and aortic vascular uptake of 18F-FDG in the aorta were associated with AWT. Following treatment of psoriasis, a decrease in aortic vascular uptake of 18F-FDG was associated with a reduction in AWT at 1 year. These findings suggest that aortic vascular uptake of 18F-FDG is associated with early evidence of vascular disease assessed by aortic wall thickness. Prospective studies in larger populations including other inflammatory diseases are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
The contribution of inflammation to the incidence of cardiovascular disease (CVD) has been increasingly recognized in recent years. We investigated the relationship of aortic vascular uptake of 18F-FDG by PET/CT and aortic wall thickness (AWT) by MRI in psoriasis, a chronic inflammatory disease with increased incidence of CVD. One hundred sixty-five patients with plaque psoriasis participated in an ongoing longitudinal cohort study. Subclinical atherosclerosis was assessed as aortic uptake of 18F-FDG by PET/CT reported as target-to-background ratio (TBR) and AWT by MRI reported as maximal thickness.
RESULTS
RESULTS
Patients with psoriasis were middle aged, predominantly male, and had mild CV risk by traditional risk factors. Psoriasis severity as measured by PASI score was a notable determinant of AWT (ρ = 0.20, p = 0.01). Moreover, aortic vascular uptake of 18F-FDG associated with AWT by MRI at baseline in unadjusted analysis (β = 0.27 p = 0.001) and following adjustment for traditional cardiovascular risk factors, waist-to-hip ratio, and statin use (β = 0.21 p = 0.01). Finally, following 1 year of psoriasis treatment, a decrease in aortic vascular uptake of 18F-FDG was associated with a reduction in AWT in fully adjusted models (β = 0.33, p = 0.02).
CONCLUSION
CONCLUSIONS
In conclusion, we demonstrate that psoriasis severity and aortic vascular uptake of 18F-FDG in the aorta were associated with AWT. Following treatment of psoriasis, a decrease in aortic vascular uptake of 18F-FDG was associated with a reduction in AWT at 1 year. These findings suggest that aortic vascular uptake of 18F-FDG is associated with early evidence of vascular disease assessed by aortic wall thickness. Prospective studies in larger populations including other inflammatory diseases are warranted.
Identifiants
pubmed: 31385013
doi: 10.1007/s00259-019-04454-w
pii: 10.1007/s00259-019-04454-w
pmc: PMC6901110
mid: NIHMS1536655
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2488-2495Subventions
Organisme : NIAMS NIH HHS
ID : K24 AR064310
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA HL006193-05
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA HL006235-01
Pays : United States
Références
Radiology. 2013 Oct;269(1):84-91
pubmed: 23781118
N Engl J Med. 2017 Sep 21;377(12):1197-1198
pubmed: 28844177
J Immunol Res. 2015;2015:759610
pubmed: 26090499
Hypertension. 2015 May;65(5):1015-9
pubmed: 25776078
N Engl J Med. 2008 Nov 20;359(21):2195-207
pubmed: 18997196
Am J Cardiol. 2008 Aug 15;102(4):491-6
pubmed: 18678312
J Vasc Surg. 2011 Apr;53(4):950-7
pubmed: 21211932
JACC Cardiovasc Imaging. 2010 Jun;3(6):605-13
pubmed: 20541716
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
Rofo. 2002 May;174(5):568-72
pubmed: 11997855
AJR Am J Roentgenol. 2004 Mar;182(3):593-7
pubmed: 14975953
JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 2):305-316
pubmed: 29055633
AJR Am J Roentgenol. 2010 Jul;195(1):229-33
pubmed: 20566821
Am J Cardiovasc Dis. 2012;2(4):285-92
pubmed: 23173102
JACC Cardiovasc Imaging. 2013 Dec;6(12):1250-9
pubmed: 24269261
Eur Heart J. 2010 Apr;31(8):1000-6
pubmed: 20037179
Circ Cardiovasc Imaging. 2016 Apr;9(4):e004043
pubmed: 27072302
JAMA Cardiol. 2018 Oct 1;3(10):949-956
pubmed: 30208407
Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):979-85
pubmed: 19183999
Br J Dermatol. 2010 Sep;163(3):586-92
pubmed: 20633008
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Circulation. 2002 Jun 11;105(23):2708-11
pubmed: 12057982
J Am Coll Cardiol. 2017 Sep 12;70(11):1403-1412
pubmed: 28882238
J Nucl Med. 2015 Apr;56(4):552-9
pubmed: 25722452
Rheumatology (Oxford). 2013 Feb;52(2):376-81
pubmed: 23065319
Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2667-76
pubmed: 26449753
N Engl J Med. 2002 Nov 14;347(20):1557-65
pubmed: 12432042
Circulation. 2002 Mar 5;105(9):1135-43
pubmed: 11877368
J Am Coll Cardiol. 2013 Sep 3;62(10):909-17
pubmed: 23727083
Am Heart J. 2013 Oct;166(4):622-628.e1
pubmed: 24093840
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii65-8; discussion ii69-73
pubmed: 15708941
J Vis Exp. 2012 May 02;(63):e3777
pubmed: 22588186
JAMA Cardiol. 2017 Sep 1;2(9):1013-1018
pubmed: 28564678